Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00424710 · ClinicalTrials.gov registry record · Phase 1
Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)
A Phase 1 study, sponsored by Hawaii Pacific Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00424710 is a Phase 1 study that has completed, run by Hawaii Pacific Health. The registered enrollment target is 17 participants.
The verdict
NCT00424710, a Phase 1 study, has completed, sponsored by Hawaii Pacific Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.
Interventions
- DRUG ranibizumab intravitreal injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2007-01 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00424710
The ClinicalTrials.gov registry entry for NCT00424710 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hawaii Pacific Health, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ranibizumab intravitreal injection is the first listed.
NCT00424710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00424710 about?
NCT00424710 is a clinical study titled "Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)". This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.
What is the current status of trial NCT00424710?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2007-01. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00424710?
The interventions under investigation include: ranibizumab intravitreal injection (DRUG).
Who is sponsoring clinical trial NCT00424710?
This trial is sponsored by Hawaii Pacific Health, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.